Abstracts tagged "autoimmune diseases"

Abstract Number: 2600 • ACR Convergence 2024
Repression of the Aryl-hydrocarbon Receptor Prevents Oxidative Stress and Ferroptosis of Intestinal γδT Cells and Alleviates Systemic Lupus Erythematosus
Qiaolin Wang¹, Yutong Wu², Qianjin Lu¹ and Ming Zhao¹, ¹Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China (People's Republic), ²Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, Second Xiangya Hospital, Central South University, Nanjing, China (People's Republic)
Background/Purpose: Dysregulation of intestinal γδT cells orchestrates the pathogenesis of various autoimmune disorders, however, its involvement in systemic lupus erythematosus (SLE) etiology remains elusive.Methods: Employing single-cell sequencing, we…
Abstract Number: 0015 • ACR Convergence 2024
Profiling of B and T Cells in Kidney Biopsies from ANCA-associated Vasculitis Patients with Glomerulonephritis at Single-Cell Resolution
Ana Merino Vico¹, Yosta Vegting¹, Aldo Jongejan¹, Jan Piet van Hamburg¹, Perry moerland¹, Sander Tas² and Marc Hilhorst¹, ¹Amsterdam UMC, Amsterdam, Netherlands, ²Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small-vessel autoimmune vasculitis, associated with severe lung and kidney impairment. B cells are crucial in AAV…
Abstract Number: 0146 • ACR Convergence 2024
Enhancing Pre-Biologic Response Modifier Screening for Coccidioidomycosis in Endemic Regions
Bashar Tanous¹, SRIKAR SAMA², Nidaa Rasheed³ and Candice Reyes⁴, ¹UCSF Fresno, Fresno, ²University of California San Francisco Fresno, Fresno, CA, ³UCSF Fresno, Fresno, CA, ⁴VACCHCS, Fresno, CA
Background/Purpose: Biologic response modifiers (BRMs), also known as "biologics," have become essential tools in treating various chronic inflammatory conditions. However, the immunosuppression caused by these agents…
Abstract Number: 0293 • ACR Convergence 2024
Assessment of Skin Cancer Risk in Autoimmune Diseases: A Multivariate Analysis Using a National Inpatient Database
Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY
Background/Purpose: Autoimmune diseases are known to be associated with an increased risk of many types of cancers. This study investigates the association between different types…
Abstract Number: 0379 • ACR Convergence 2024
Effectiveness and Safety of Baricitinib for the Treatment of Juvenile Idiopathic Arthritis Associated Uveitis or Chronic Anterior Antinuclear Antibody Positive Uveitis in Children
Athimalaipet Ramanan¹, Catherine Guly², Gabriele Simonini³, Stuart Keller⁴, Priyanka Sen⁴, Thorsten Holzkaemper⁴ and PIERRE QUARTIER⁵, ¹Bristol Royal Hosp for Children, Bristol, United Kingdom, ²University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom, ³Meyer Children’s Hospital IRCCS; University of Florence, Florence, Toscana, Italy, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Université Paris-Cite, IMAGINE Institute, Necker Children’s Hospital, Paris Cedex 15, France
Background/Purpose: Baricitinib could target multiple cytokine pathways associated with juvenile idiopathic arthritis associated uveitis (JIA-U) and antinuclear antibody (ANA)-positive uveitis, providing a novel therapeutic approach.…
Abstract Number: 0607 • ACR Convergence 2024
Plasma Proteomic Analysis Reveals Type I Interferon Blockade Effects of Anifrolumab in Lupus Nephritis: Insights from a Phase 2 Trial
Andrea Fava¹, Michelle Petri², David Jayne³, Patrick G Gavin⁴, Eszter Csomor⁵, Philip Z Brohawn⁴, Daniel Muthas⁶, Adam Platt⁵, Catharina Lindholm⁷ and Nicola Ferrari⁵, ¹Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD, ³University of Cambridge, Cambridge, United Kingdom, ⁴BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁵BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁶BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁷BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden
Background/Purpose: An elevated type I interferon gene signature (IFNGS) is associated with more active disease in patients with LN.1 Anifrolumab, a type I interferon receptor…
Abstract Number: 0780 • ACR Convergence 2024
Deep B Cell Tissue Depletion Following Anti-CD19 CART Cells Therapy
Carlo Tur¹, Markus Eckstein², Velden Joachim³, Christina Bergmann⁴, Janina Auth¹, Laura Bucci¹, Giulia Corte⁵, Melanie Hagen¹, Andreas Wirsching¹, Ricardo Grieshaber-Bouyer¹, Petra Reis¹, Nicolai Kittan¹, Jochen Wacker¹, Simon Rauber¹, Aleix Rigau⁶, Andreas Ramming¹, Maria Antonietta D'Agostino⁷, Arndt Hartmann⁸, Fabian Müller⁹, Andreas MAckensen¹⁰, Aline Bozec¹, Georg Schett¹¹ and Maria Gabriella Raimondo¹, ¹Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ²Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ³Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁴Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁵Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, ⁶Friedrich-Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁷Division of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Università Cattolica del Sacro Cuore, Rome, Italy, ⁸Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ⁹Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ¹⁰Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ¹¹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has proved potential for achieving long-term drug-free remission in patients with autoimmune diseases (AIDs). Its effectiveness likely…
Abstract Number: 0889 • ACR Convergence 2024
Unraveling the Progression of Sjögren’s Disease at the Cellular and Histological Level Using Single-cell and Spatial Transcriptomics
Tomás Gomes¹, Matilde Bandeira², Rui do Amaral Vieira¹, Bianca Correia¹, Sofia Barreira³, Pedro Gaspar⁴, Rita Cruz-Machado⁵, Beatriz Filipe¹, Pedro Ávila-Ribeiro¹, Filipa Ribeiro¹, Bruno Vidal¹, Beatriz Val¹, Filipa Costa⁶, Ana Teodósio Chícharo⁷, Augusto Silva¹, Manuel Silvério-Antonio¹, João Forjaz Lacerda¹, João Eurico Fonseca¹, Dolores López Presa⁸, Nikita Khmelinskii¹, Saumya Kumar⁹, Luis Graca¹ and Vasco C. Romão¹⁰, ¹Instituto de Medicina Molecular (iMM Lisboa), Lisboa, Portugal, ²Centro Hospitalar Universitario Lisboa Norte, Lisboa, Portugal, ³Unidade Local de Saúde Santa Maria, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Lisboa, Portugal, Lisbon, Portugal, ⁴Internal Medicine Department, Hospital Santa Maria, Unidade Local de Saúde Santa Maria, Lisbon, Portugal, Povoa de Santa Iria, Portugal, ⁵Unidade Local de Saúde Santa Maria, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Lisboa, Portugal, Lisboa, Portugal, ⁶Rheumatology Department, Unidade Local de Saúde de Santa Maria. Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Lisbon, Portugal, ⁷Unidade Local de Saúde do Algarve, Hospital de Faro, Faro, Portugal, Faro, Portugal, ⁸Pathology Department, Unidade Local de Saúde de Santa Maria, Lisbon Academic Medical Centre, Lisboa, Portugal, ⁹TWINCORE, a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany, Hannover, Germany, ¹⁰Rheumatology Department, ULS Santa Maria & Rheumatology Research Unit, Instituto Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal
Background/Purpose: Sjögren’s Disease (SjD) is a systemic autoimmune disease that primarily targets salivary and lacrimal glands, causing tissue deterioration and loss of function. Disease progression…
Abstract Number: 0969 • ACR Convergence 2024
Role and Mechanism of the Wnt3a-FZD5 Pathway in Regulating the Transformed Intermediate State of Alveolar Epithelial Cells Involved in Pulmonary Fibrosis in Systemic Sclerosis
Hang Yu¹ and Jing Xue², ¹zhejiang university, Hangzhou, China (People's Republic), ²The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China (People's Republic)
Background/Purpose: Systemic sclerosis (SSc) is a diffuse connective tissue disease associated with multi-system and multi-organ tissue damage. The transformation of different precursor cells to myofibroblasts…
Abstract Number: 1127 • ACR Convergence 2024
Risk of Ocular Inflammatory Conditions in Patients with Autoimmune Diseases: A Retrospective Study Using the National Inpatient Sample
Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY
Background/Purpose: Autoimmune diseases are known to cause various ocular inflammatory conditions and are often the initial presentation in many of these diseases. This study aims…
Abstract Number: 1414 • ACR Convergence 2024
Evidence-Based Guidelines for Sjögren’s Disease Peripheral Nervous System Manifestations
Robert Fox¹, Anahita Deboo², Matthew Baker³, Stamatina Danielides⁴, Eduardo de Sousa⁵, Julie Frantsve Hawley⁶, Brent Goodman⁷, Katherine Hammitt⁶, Jennifer King⁸, Matt Makara⁶, Steven Mandel⁹, Ghaith Noaiseh¹⁰, Pantelis Pavlakis¹¹, George Sarka¹², Arun Varadhachary¹³, Daniel Wallace¹⁴, Robert Hal Scofield¹⁵, Nancy Carteron¹⁶ and Steven Carsons¹⁷, ¹Rheumatology Clinic, San Diego, CA, ²Temple University, Philadelphia, ³Stanford University, Menlo Park, CA, ⁴Vcu, Glen Allen, VA, ⁵Mercy, Moore, OK, ⁶Sjogren's Foundation, Reston, VA, ⁷Mayo Clinic, Scottsdale, AZ, ⁸UCLA, Los Angeles, CA, ⁹Hofstra, Hempstead, ¹⁰University of Kansas Medical Center, Kansas City, KS, ¹¹Hospital for Special Surgery, New York, NY, ¹²UCLA, Laguna Hills, CA, ¹³Washington University in St. Louis, St. Louis, MO, ¹⁴Cedars Sinai Medical Center, Studio City, CA, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶University of California, Berkeley & San Francisco, Angwin, CA, ¹⁷NYU Long Island School of Medicine, Mineola, NY
Background/Purpose: Peripheral Nervous System (PNS) manifestations occur frequently in Sjögren’s disease and can encompass mononeuropathy, polyneuropathy, and autonomic neuropathy. Guidance is needed for rheumatologists, neurologists,…
Abstract Number: 1565 • ACR Convergence 2024
Prevalence and Risk Factors of Lower Extremities Arterial Disease in Systemic Sclerosis: Preliminary Data from a Single Centre Multidisciplinary Study
Maria-Grazia Lazzaroni¹, Paolo Baggi², Liala Moschetti¹, Eleonora Pedretti³, Elda Piovani¹, Claudia Barison¹, Emma Manzoni⁴, Franco Franceschini¹, Stefano Bonardelli² and Paolo Airò¹, ¹Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ²Vascular Surgery Unit, ASST Spedali Civili of Brescia, University of Brescia, Italy, Brescia, Italy, ³Scleroderma Unit, Rheumatology Unit, ERN ReCONNET, ASST Spedali Civili and University of Brescia; Italy, Brescia, Italy, ⁴University of Brescia, Brescia, Italy
Background/Purpose: Microvascular changes represent a key step of pathogenic process in Systemic Sclerosis (SSc). However, SSc has been demonstrated to carry an increased risk of…
Abstract Number: 1692 • ACR Convergence 2024
Single Cell RNA-seq Identifies Circulating Double-negative-2 B-cell Population Associated with Progressive Scleroderma Interstitial Lung Disease
Trinitee Oliver¹, Kim Taylor², Ye Cao³, Takanori Sasaki⁴, Deepak Rao⁵, Nunzio Bottini⁶, Francesco Boin⁶ and Richard Ainsworth⁶, ¹Cedars-Sinai Medical Center, Hawthorne, CA, ²University of California, San Francisco, CA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Brookline, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: B-cell subsets display aberrant function in systemic sclerosis (SSc) pathogenesis and infiltrate the lungs of SSc patients with interstitial lung disease (ILD). B-cells relevance…
Abstract Number: 1825 • ACR Convergence 2024
Proteomic and Transcriptomic Analysis Reveal Elevated Senescent Signature in Systemic Sclerosis Fibrosis
Poulami Dey, Hiroshi Kato, Suiyuan Huang, Johann Gudjonsson, Dinesh Khanna, John Varga and Eliza Pei-Suen Tsou, University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is marked by persistent fibrosis affecting both the skin and internal organs. Some regard SSc as a manifestation of expedited aging,…
Abstract Number: 1887 • ACR Convergence 2024
High Rates of Cost-Related Medication Non-Adherence Among Younger Patients Receiving Immunosuppression Are Exacerbated by Other Chronic Conditions
Samuel Good¹, Bryant England² and Elizabeth Volkmann³, ¹University of California, Los Angeles, Los Angeles, CA, ²University of Nebraska Medical Center, Omaha, NE, ³University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles
Background/Purpose: Medication non-adherence is associated with worse autoimmune disease outcomes; however, it is unknown whether adherence rates related to cost barriers differ across diseases and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].